Stuart, Robert K.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,287

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 991

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283

Harris, J. E., Ryan, L., Hoover, H. C., Stuart, R. K., Oken, M. M., Benson, A. B., Mansour, E., Haller, D. G., Manola, J., & Hanna, M. G. (2000) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesColorectal Cancer Treatments and Studies

Cited by 273

Final results of a phase III randomized trial of CPX-351 versus 7+ 3 in older patients with newly diagnosed high risk (secondary) AML

Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2016) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 164

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 48